Rubedo Life Sciences is a technology company.
Rubedo Life Sciences has raised $52.0M across 2 funding rounds.
Rubedo Life Sciences has raised $52.0M in total across 2 funding rounds.
Rubedo Life Sciences has raised $52.0M in total across 2 funding rounds.
Rubedo Life Sciences's investors include 7percent Ventures, Ahren Innovation Capital, Alumni Ventures, Catalio Capital, Gaingels, Khosla Ventures, MarsBio, Moonstone Venture Capital, Presight Capital, Refactor Capital, SOSV, The House Fund.
Rubedo Life Sciences is a Silicon Valley-based biotechnology company developing small-molecule drugs to extend human healthspan by targeting pathologic cells that drive aging, such as senescent cells, while enhancing beneficial ones like stem cells.[1][2] It addresses age-related diseases including Alzheimer's, cancer, diabetes, arthritis, sarcopenia, psoriasis, and respiratory conditions, with a pipeline in preclinical and discovery stages focused on nervous system, metabolic, immune, and musculoskeletal disorders.[1][4] The company serves patients seeking longevity therapies and has raised seed funding as a private entity, building momentum through expertise from top institutions like Stanford, Berkeley, and Cambridge.[1][3]
Founded in 2018 in Sunnyvale, California, Rubedo Life Sciences emerged from a collaboration among leading scientists and entrepreneurs passionate about aging biology and therapeutics.[1][2] Key founders Julian Klein, Marco Quarta, and Mark Gallop bring backgrounds from academia (Stanford, Berkeley, Cambridge) and industry (Affymax, Xenoport, Verily), uniting combinatorial chemistry, regenerative medicine, and senescence research to create innovative drugs.[1][3] Early traction stemmed from this "crucible of innovations," positioning Rubedo to tackle cellular drivers of aging with precise small molecules and stem cell approaches.[1][2]
Rubedo rides the surging longevity biotech trend, where targeting cellular senescence addresses root causes of multiple age-related diseases amid rising investment in healthspan extension.[1][2] Timing aligns with advances in medicinal chemistry and regenerative medicine from elite institutions, fueled by market forces like aging populations and successes in related fields (e.g., Verily's influence).[1][3] It influences the ecosystem by advancing preclinical pipelines in high-burden areas like neurodegeneration and metabolism, potentially accelerating small-molecule therapies for systemic aging.[4]
Rubedo is poised to advance its preclinical candidates into clinical trials, prioritizing high-impact indications like sarcopenia and nervous system diseases amid booming longevity funding.[4] Trends in AI-driven drug discovery and senolytics will shape its path, potentially amplifying influence through partnerships with big pharma given its pedigreed team.[3] As a seed-stage leader, expect milestone readouts and series A expansion, solidifying its role in biologically preserving youth against aging's cellular assault—echoing its mission to keep humanity healthier longer.[2]
Rubedo Life Sciences has raised $52.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $40.0M Series A | 7percent Ventures, Ahren Innovation Capital, Alumni Ventures, Catalio Capital, Gaingels, Khosla Ventures, MarsBio, Moonstone Venture Capital, Presight Capital, Refactor Capital, SOSV, The House Fund, The Longevity Fund, Tiger Global Management, TLV Partners, Tuesday Capital, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Dan Ciporin, Dylan Field, Fidji Simo, Justin Mateen, Rich Miner, Varsha Rao | |
| Dec 1, 2020 | $12.0M Seed | 7percent Ventures, Ahren Innovation Capital, Alumni Ventures, Catalio Capital, Gaingels, Khosla Ventures, Moonstone Venture Capital, Refactor Capital, The Longevity Fund, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Dylan Field, Fidji Simo, Varsha Rao |